The Complexity of Targeting Chemokines to Promote a Tumor Immune Response.


Journal

Inflammation
ISSN: 1573-2576
Titre abrégé: Inflammation
Pays: United States
ID NLM: 7600105

Informations de publication

Date de publication:
Aug 2020
Historique:
pubmed: 22 4 2020
medline: 11 6 2021
entrez: 22 4 2020
Statut: ppublish

Résumé

Immunotherapeutic treatment strategies greatly extend patient survival following malignant disease across a wide range of tumor types, including even those with metastatic disease. While diverse in approach, adoptive cell therapy, introduction of T cells that express chimeric antigen receptors, and checkpoint inhibitors all aim to re-invigorate the immune system to promote tumor cell identification and elimination. This review will focus on immune cell infiltration into tumors as well as a cellular organization within the tumor microenvironment as directed by the cell-specific expression patterns of chemokines and chemokine receptors. Through better understanding the chemokine network within tumors, we can uncover mechanisms to promote beneficial immune cell infiltration that can be combined with checkpoint inhibition. Conversely, chemokine expression is not limited to cells of the immune system, and it is understood that tumor cells also express chemokines and chemokine receptors. Tumor cells can hijack the chemokine networks to promote immune suppression and metastatic tumor cell trafficking. We will discuss the ways in which the chemokine network lies at the crossroad of immune evasion and tumor regression. Overall, this review will summarize key publications in the field of immune cell recruitment to tumors, highlight the dichotomous nature of chemokine interventions into cancer, and aims to identify therapeutic pathways forward.

Identifiants

pubmed: 32314127
doi: 10.1007/s10753-020-01235-8
pii: 10.1007/s10753-020-01235-8
pmc: PMC8270394
mid: NIHMS1586113
doi:

Substances chimiques

Chemokines 0
Immune Checkpoint Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1201-1208

Subventions

Organisme : National Institutes of Health (US)
ID : CA231277
Organisme : NIAID NIH HHS
ID : R01 AI125640
Pays : United States
Organisme : NIH HHS
ID : AI25640
Pays : United States
Organisme : Cancer Research Institute
ID : NA
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA231277
Pays : United States

Références

Holmes, W.E., J. Lee, W.J. Kuang, G.C. Rice, and W.I. Wood. 1991. Structure and functional expression of a human interleukin-8 receptor. Science 253 (5025): 1278–1280. https://doi.org/10.1126/science.1840701 .
doi: 10.1126/science.1840701 pubmed: 1840701
Murphy, P.M., and H.L. Tiffany. 1991. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 253 (5025): 1280–1283. https://doi.org/10.1126/science.1891716 .
doi: 10.1126/science.1891716 pubmed: 1891716
Rollins, B.J. 2009. Where the confusion began: cloning the first chemokine receptors. Journal of Immunology 183 (5): 2893–2894. https://doi.org/10.4049/jimmunol.0990065 .
doi: 10.4049/jimmunol.0990065
Strazza, M., and A. Mor. 2017. Consider the chemokines: a review of the interplay between chemokines and T cell subset function. Discovery Medicine 24 (130): 31–39.
pubmed: 28950073 pmcid: 8266128
Balkwill, F. 2004. Cancer and the chemokine network. Nature Reviews: Cancer 4 (7): 540–550. https://doi.org/10.1038/nrc1388 .
doi: 10.1038/nrc1388 pubmed: 15229479
Charo, I.F., and R.M. Ransohoff. 2006. The many roles of chemokines and chemokine receptors in inflammation. New England Journal of Medicine 354 (6): 610–621. https://doi.org/10.1056/NEJMra052723 .
doi: 10.1056/NEJMra052723
Chow, M.T., and A.D. Luster. 2014. Chemokines in cancer. Cancer Immunology Research 2 (12): 1125–1131. https://doi.org/10.1158/2326-6066.CIR-14-0160 .
doi: 10.1158/2326-6066.CIR-14-0160 pubmed: 25480554 pmcid: 4258879
Strazza, M., I. Azoulay-Alfaguter, G.J. Silverman, and A. Mor. 2015. T cell chemokine receptor patterns as pathogenic signatures in autoimmunity. Discovery Medicine 19 (103): 117–125.
pubmed: 25725226
Chow, M.T., A.J. Ozga, R.L. Servis, D.T. Frederick, J.A. Lo, D.E. Fisher, G.J. Freeman, G.M. Boland, and A.D. Luster. 2019. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50 (6): 1498–1512 e1495. https://doi.org/10.1016/j.immuni.2019.04.010 .
doi: 10.1016/j.immuni.2019.04.010 pubmed: 31097342 pmcid: 6527362
Ascierto, P.A., K.D. Lewis, A.M. Di Giacomo, L. Demidov, M. Mandala, I. Bondarenko, C. Herbert, et al. 2020. Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF(v600) mutation-positive melanoma receiving adjuvant vemurafenib. Annals of Oncology 31 (1): 153–159. https://doi.org/10.1016/j.annonc.2019.10.002 .
doi: 10.1016/j.annonc.2019.10.002 pubmed: 31912791
Herbst, R.S., J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D. McDermott, J.D. Powderly, S.N. Gettinger, H.E. Kohrt, L. Horn, D.P. Lawrence, S. Rost, M. Leabman, Y. Xiao, A. Mokatrin, H. Koeppen, P.S. Hegde, I. Mellman, D.S. Chen, and F.S. Hodi. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (7528): 563–567. https://doi.org/10.1038/nature14011 .
doi: 10.1038/nature14011 pubmed: 25428504 pmcid: 4836193
Jessurun, C.A.C., J.A.M. Vos, J. Limpens, and R.M. Luiten. 2017. Biomarkers for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Frontiers in Oncology 7: 233. https://doi.org/10.3389/fonc.2017.00233 .
doi: 10.3389/fonc.2017.00233 pubmed: 29034210 pmcid: 5625582
Hegde, P.S., V. Karanikas, and S. Evers. 2016. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clinical Cancer Research 22 (8): 1865–1874. https://doi.org/10.1158/1078-0432.CCR-15-1507 .
doi: 10.1158/1078-0432.CCR-15-1507 pubmed: 27084740
Chen, D.S., and I. Mellman. 2017. Elements of cancer immunity and the cancer-immune set point. Nature 541 (7637): 321–330. https://doi.org/10.1038/nature21349 .
doi: 10.1038/nature21349 pubmed: 28102259
Ribas, A., and J.D. Wolchok. 2018. Cancer immunotherapy using checkpoint blockade. Science 359 (6382): 1350–1355. https://doi.org/10.1126/science.aar4060 .
doi: 10.1126/science.aar4060 pubmed: 29567705 pmcid: 7391259
Ben-Baruch, A. 2006. The multifaceted roles of chemokines in malignancy. Cancer and Metastasis Reviews 25 (3): 357–371. https://doi.org/10.1007/s10555-006-9003-5 .
doi: 10.1007/s10555-006-9003-5 pubmed: 17016763
Zlotnik, A., A.M. Burkhardt, and B. Homey. 2011. Homeostatic chemokine receptors and organ-specific metastasis. Nature Reviews: Immunology 11 (9): 597–606. https://doi.org/10.1038/nri3049 .
doi: 10.1038/nri3049 pubmed: 21866172
Idorn, M., and P. Thor Straten. 2018. Chemokine receptors and exercise to tackle the inadequacy of T cell homing to the tumor site. Cells 7 (8). https://doi.org/10.3390/cells7080108 .
Bilusic, M., C.R. Heery, J.M. Collins, R.N. Donahue, C. Palena, R.A. Madan, F. Karzai, J.L. Marté, J. Strauss, M.E. Gatti-Mays, J. Schlom, and J.L. Gulley. 2019. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. Journal for Immunotherapy of Cancer 7 (1): 240. https://doi.org/10.1186/s40425-019-0706-x .
doi: 10.1186/s40425-019-0706-x pubmed: 31488216 pmcid: 6729083
Liu, C., S. Zheng, R. Jin, X. Wang, F. Wang, R. Zang, H. Xu, et al. 2019. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Letters. https://doi.org/10.1016/j.canlet.2019.10.027 .
Spranger, S., R. Bao, and T.F. Gajewski. 2015. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523 (7559): 231–235. https://doi.org/10.1038/nature14404 .
doi: 10.1038/nature14404 pubmed: 25970248
Li, F., S. Kitajima, S. Kohno, A. Yoshida, S. Tange, S. Sasaki, N. Okada, Y. Nishimoto, H. Muranaka, N. Nagatani, M. Suzuki, S. Masuda, T.C. Thai, T. Nishiuchi, T. Tanaka, D.A. Barbie, N. Mukaida, and C. Takahashi. 2019. Retinoblastoma inactivation induces a protumoral microenvironment via enhanced CCL2 secretion. Cancer Research 79 (15): 3903–3915. https://doi.org/10.1158/0008-5472.CAN-18-3604 .
doi: 10.1158/0008-5472.CAN-18-3604 pubmed: 31189648
Peng, W., J.Q. Chen, C. Liu, S. Malu, C. Creasy, M.T. Tetzlaff, C. Xu, J. McKenzie, C. Zhang, X. Liang, L.J. Williams, W. Deng, G. Chen, R. Mbofung, A.J. Lazar, C.A. Torres-Cabala, Z.A. Cooper, P.L. Chen, T.N. Tieu, S. Spranger, X. Yu, C. Bernatchez, M.A. Forget, C. Haymaker, R. Amaria, J. McQuade, I.C. Glitza, T. Cascone, H.S. Li, L.N. Kwong, T.P. Heffernan, J. Hu, Bassett RL Jr, M.W. Bosenberg, S.E. Woodman, W.W. Overwijk, G. Lizée, J. Roszik, T.F. Gajewski, J.A. Wargo, J.E. Gershenwald, L. Radvanyi, M.A. Davies, and P. Hwu. 2016. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery 6 (2): 202–216. https://doi.org/10.1158/2159-8290.CD-15-0283 .
doi: 10.1158/2159-8290.CD-15-0283 pubmed: 26645196
Huang, H., E. Langenkamp, M. Georganaki, A. Loskog, P.F. Fuchs, L.C. Dieterich, J. Kreuger, and A. Dimberg. 2015. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation. FASEB Journal 29 (1): 227–238. https://doi.org/10.1096/fj.14-250985 .
doi: 10.1096/fj.14-250985 pubmed: 25361735
Viola, A., A. Sarukhan, V. Bronte, and B. Molon. 2012. The pros and cons of chemokines in tumor immunology. Trends in Immunology 33 (10): 496–504. https://doi.org/10.1016/j.it.2012.05.007 .
doi: 10.1016/j.it.2012.05.007 pubmed: 22726608
Zsiros, E., P. Duttagupta, D. Dangaj, H. Li, R. Frank, T. Garrabrant, I.S. Hagemann, B.L. Levine, C.H. June, L. Zhang, E. Wang, F.M. Marincola, D. Bedognetti, Powell DJ Jr, J. Tanyi, M.D. Feldman, L.E. Kandalaft, and G. Coukos. 2015. The ovarian cancer chemokine landscape is conducive to homing of vaccine-primed and CD3/CD28-costimulated T cells prepared for adoptive therapy. Clinical Cancer Research 21 (12): 2840–2850. https://doi.org/10.1158/1078-0432.CCR-14-2777 .
doi: 10.1158/1078-0432.CCR-14-2777 pubmed: 25712684 pmcid: 4987088
Harlin, H., Y. Meng, A.C. Peterson, Y. Zha, M. Tretiakova, C. Slingluff, M. McKee, and T.F. Gajewski. 2009. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Research 69 (7): 3077–3085. https://doi.org/10.1158/0008-5472.CAN-08-2281 .
doi: 10.1158/0008-5472.CAN-08-2281 pubmed: 19293190
Sackstein, R., T. Schatton, and S.R. Barthel. 2017. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Laboratory Investigation 97 (6): 669–697. https://doi.org/10.1038/labinvest.2017.25 .
doi: 10.1038/labinvest.2017.25 pubmed: 28346400
Dangaj, D., M. Bruand, A.J. Grimm, C. Ronet, D. Barras, P.A. Duttagupta, E. Lanitis, J. Duraiswamy, J.L. Tanyi, F. Benencia, J. Conejo-Garcia, H.R. Ramay, K.T. Montone, Powell DJ Jr, P.A. Gimotty, A. Facciabene, D.G. Jackson, J.S. Weber, S.J. Rodig, S.F. Hodi, L.E. Kandalaft, M. Irving, L. Zhang, P. Foukas, S. Rusakiewicz, M. Delorenzi, and G. Coukos. 2019. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell 35 (6): 885–900 e810. https://doi.org/10.1016/j.ccell.2019.05.004 .
doi: 10.1016/j.ccell.2019.05.004 pubmed: 31185212 pmcid: 6961655
Mikucki, M.E., D.T. Fisher, J. Matsuzaki, J.J. Skitzki, N.B. Gaulin, J.B. Muhitch, A.W. Ku, J.G. Frelinger, K. Odunsi, T.F. Gajewski, A.D. Luster, and S.S. Evans. 2015. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nature Communications 6: 7458. https://doi.org/10.1038/ncomms8458 .
doi: 10.1038/ncomms8458 pubmed: 26109379
Triozzi, P.L., L. Schoenfield, T. Plesec, Y. Saunthararajah, R.R. Tubbs, and A.D. Singh. 2019. Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes. Oncoimmunology 8 (10): e947169. https://doi.org/10.4161/21624011.2014.947169 .
doi: 10.4161/21624011.2014.947169 pubmed: 31646061
Strazza, M., K. Adam, A.V. Smrcka, S. Lerrer, and A. Mor. 2020. PLCepsilon1 suppresses tumor growth by regulating murine T cell mobilization. Clinical and Experimental Immunology 200 (1): 53–60. https://doi.org/10.1111/cei.13409 .
doi: 10.1111/cei.13409 pubmed: 31867717 pmcid: 7066383
Strazza, M., I. Azoulay-Alfaguter, M. Peled, A.V. Smrcka, E.Y. Skolnik, S. Srivastava, and A. Mor. 2017. PLCepsilon1 regulates SDF-1alpha-induced lymphocyte adhesion and migration to sites of inflammation. Proceedings of the National Academy of Sciences of the United States of America 114 (10): 2693–2698. https://doi.org/10.1073/pnas.1612900114 .
doi: 10.1073/pnas.1612900114 pubmed: 28213494 pmcid: 5347583
Jin, L., H. Tao, A. Karachi, Y. Long, A.Y. Hou, M. Na, K.A. Dyson, A.J. Grippin, L.P. Deleyrolle, W. Zhang, D.A. Rajon, Q.J. Wang, J.C. Yang, J.L. Kresak, E.J. Sayour, M. Rahman, F.J. Bova, Z. Lin, D.A. Mitchell, and J. Huang. 2019. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nature Communications 10 (1): 4016. https://doi.org/10.1038/s41467-019-11869-4 .
doi: 10.1038/s41467-019-11869-4 pubmed: 31488817 pmcid: 6728370
Whilding, L.M., L. Halim, B. Draper, A.C. Parente-Pereira, T. Zabinski, D.M. Davies, and J. Maher. 2019. CAR T-cells targeting the integrin alphavbeta6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers 11 (5). https://doi.org/10.3390/cancers11050674 .
Donia, M., N. Junker, E. Ellebaek, M.H. Andersen, P.T. Straten, and I.M. Svane. 2012. Characterization and comparison of ‘standard’ and ‘young’ tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Scandinavian Journal of Immunology 75 (2): 157–167. https://doi.org/10.1111/j.1365-3083.2011.02640.x .
doi: 10.1111/j.1365-3083.2011.02640.x pubmed: 21955245
Rosenberg, S.A., J.C. Yang, R.M. Sherry, U.S. Kammula, M.S. Hughes, G.Q. Phan, D.E. Citrin, N.P. Restifo, P.F. Robbins, J.R. Wunderlich, K.E. Morton, C.M. Laurencot, S.M. Steinberg, D.E. White, and M.E. Dudley. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research 17 (13): 4550–4557. https://doi.org/10.1158/1078-0432.CCR-11-0116 .
doi: 10.1158/1078-0432.CCR-11-0116 pubmed: 21498393 pmcid: 3131487
Dudley, M.E., J.R. Wunderlich, T.E. Shelton, J. Even, and S.A. Rosenberg. 2003. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. Journal of Immunotherapy 26 (4): 332–342. https://doi.org/10.1097/00002371-200307000-00005 .
doi: 10.1097/00002371-200307000-00005 pubmed: 12843795
Sapoznik, S., R. Ortenberg, G. Galore-Haskel, S. Kozlovski, D. Levy, C. Avivi, I. Barshack, C.J. Cohen, M.J. Besser, J. Schachter, and G. Markel. 2012. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunology, Immunotherapy 61 (10): 1833–1847. https://doi.org/10.1007/s00262-012-1245-1 .
doi: 10.1007/s00262-012-1245-1 pubmed: 22441657
Idorn, M., P. Thor Straten, I.M. Svane, and O. Met. 2016. Transfection of tumor-infiltrating T cells with mRNA encoding CXCR2. Methods in Molecular Biology 1428: 261–276. https://doi.org/10.1007/978-1-4939-3625-0_17 .
doi: 10.1007/978-1-4939-3625-0_17 pubmed: 27236805
Peng, W., Y. Ye, B.A. Rabinovich, C. Liu, Y. Lou, M. Zhang, M. Whittington, Y. Yang, W.W. Overwijk, G. Lizée, and P. Hwu. 2010. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clinical Cancer Research 16 (22): 5458–5468. https://doi.org/10.1158/1078-0432.CCR-10-0712 .
doi: 10.1158/1078-0432.CCR-10-0712 pubmed: 20889916 pmcid: 3476703
Kershaw, M.H., G. Wang, J.A. Westwood, R.K. Pachynski, H.L. Tiffany, F.M. Marincola, E. Wang, H.A. Young, P.M. Murphy, and P. Hwu. 2002. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Human Gene Therapy 13 (16): 1971–1980. https://doi.org/10.1089/10430340260355374 .
doi: 10.1089/10430340260355374 pubmed: 12427307
Murata, K., T. Tsukahara, M. Emori, Y. Shibayama, E. Mizushima, H. Matsumiya, K. Yamashita, M. Kaya, Y. Hirohashi, T. Kanaseki, T. Kubo, T. Himi, S. Ichimiya, T. Yamashita, N. Sato, and T. Torigoe. 2016. Identification of a novel human memory T-cell population with the characteristics of stem-like chemo-resistance. Oncoimmunology 5 (6): e1165376. https://doi.org/10.1080/2162402X.2016.1165376 .
doi: 10.1080/2162402X.2016.1165376 pubmed: 27471640 pmcid: 4938359
Gattinoni, L., C.A. Klebanoff, and N.P. Restifo. 2012. Paths to stemness: building the ultimate antitumour T cell. Nature Reviews: Cancer 12 (10): 671–684. https://doi.org/10.1038/nrc3322 .
doi: 10.1038/nrc3322 pubmed: 22996603
Gattinoni, L., E. Lugli, Y. Ji, Z. Pos, C.M. Paulos, M.F. Quigley, J.R. Almeida, E. Gostick, Z. Yu, C. Carpenito, E. Wang, D.C. Douek, D.A. Price, C.H. June, F.M. Marincola, M. Roederer, and N.P. Restifo. 2011. A human memory T cell subset with stem cell-like properties. Nature Medicine 17 (10): 1290–1297. https://doi.org/10.1038/nm.2446 .
doi: 10.1038/nm.2446 pubmed: 21926977 pmcid: 3192229
Di Stasi, A., B. De Angelis, C.M. Rooney, L. Zhang, A. Mahendravada, A.E. Foster, H.E. Heslop, M.K. Brenner, G. Dotti, and B. Savoldo. 2009. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113 (25): 6392–6402. https://doi.org/10.1182/blood-2009-03-209650 .
doi: 10.1182/blood-2009-03-209650 pubmed: 19377047 pmcid: 2710932
Gowrishankar, K., L. Birtwistle, and K. Micklethwaite. 2018. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mammalian Genome 29 (11–12): 739–756. https://doi.org/10.1007/s00335-018-9756-5 .
doi: 10.1007/s00335-018-9756-5 pubmed: 29987406
Craddock, J.A., A. Lu, A. Bear, M. Pule, M.K. Brenner, C.M. Rooney, and A.E. Foster. 2010. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. Journal of Immunotherapy 33 (8): 780–788. https://doi.org/10.1097/CJI.0b013e3181ee6675 .
doi: 10.1097/CJI.0b013e3181ee6675 pubmed: 20842059
Lesokhin, A.M., T.M. Hohl, S. Kitano, C. Cortez, D. Hirschhorn-Cymerman, F. Avogadri, G.A. Rizzuto, J.J. Lazarus, E.G. Pamer, A.N. Houghton, T. Merghoub, and J.D. Wolchok. 2012. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Research 72 (4): 876–886. https://doi.org/10.1158/0008-5472.CAN-11-1792 .
doi: 10.1158/0008-5472.CAN-11-1792 pubmed: 22174368
Mollica Poeta, V., M. Massara, A. Capucetti, and R. Bonecchi. 2019. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Frontiers in Immunology 10: 379. https://doi.org/10.3389/fimmu.2019.00379 .
doi: 10.3389/fimmu.2019.00379 pubmed: 30894861 pmcid: 6414456
Luster, A.D., and P. Leder. 1993. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. Journal of Experimental Medicine 178 (3): 1057–1065. https://doi.org/10.1084/jem.178.3.1057 .
doi: 10.1084/jem.178.3.1057
House, I.G., P. Savas, J. Lai, A.X.Y. Chen, A.J. Oliver, Z.L. Teo, K.L. Todd, et al. 2019. Macrophage derived CXCL9 and CXCL10 are required for anti-tumor immune responses following immune checkpoint blockade. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-19-1868 .
Pascual-Garcia, M., E. Bonfill-Teixidor, E. Planas-Rigol, C. Rubio-Perez, R. Iurlaro, A. Arias, I. Cuartas, et al. 2019. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy. Nature Communications 10 (1): 2416. https://doi.org/10.1038/s41467-019-10369-9 .
doi: 10.1038/s41467-019-10369-9 pubmed: 31186412 pmcid: 6559950
Yan, M., N. Jene, D. Byrne, E.K. Millar, S.A. O'Toole, C.M. McNeil, G.J. Bates, et al. 2011. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research 13 (2): R47. https://doi.org/10.1186/bcr2869 .
doi: 10.1186/bcr2869 pubmed: 21521526 pmcid: 3219210
Zeng, Y., B. Li, Y. Liang, P.M. Reeves, X. Qu, C. Ran, Q. Liu, M.V. Callahan, A.E. Sluder, J.A. Gelfand, H. Chen, and M.C. Poznansky. 2019. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB Journal 33 (5): 6596–6608. https://doi.org/10.1096/fj.201802067RR .
doi: 10.1096/fj.201802067RR pubmed: 30802149 pmcid: 6463916
Saxena, R., Y. Wang, and J.W. Mier. 2019. CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors. Melanoma Research. https://doi.org/10.1097/CMR.0000000000000639 .
Wu, A., R. Maxwell, Y. Xia, P. Cardarelli, M. Oyasu, Z. Belcaid, E. Kim, A. Hung, A.S. Luksik, T. Garzon-Muvdi, C.M. Jackson, D. Mathios, D. Theodros, J. Cogswell, H. Brem, D.M. Pardoll, and M. Lim. 2019. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. Journal of Neuro-Oncology 143 (2): 241–249. https://doi.org/10.1007/s11060-019-03172-5 .
doi: 10.1007/s11060-019-03172-5 pubmed: 31025274
Medicine, U.S. National Library of. 2017. Olaptesed (NOX-A12) alone and in combination with pembrolizumab in colorectal and pancreatic cancer (Keynote-559). https://clinicaltrials.gov/ct2/show/NCT03168139 . Accessed Nov 18, 2019.

Auteurs

Marianne Strazza (M)

Columbia Center for Translational Immunology, Columbia University Medical Center, 650 W 168 St. BB-1708, New York, NY, 10032, USA. ms5800@CUMC.Columbia.edu.

Adam Mor (A)

Columbia Center for Translational Immunology, Columbia University Medical Center, 650 W 168 St. BB-1708, New York, NY, 10032, USA. am5121@CUMC.Columbia.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH